New measure of tumour mutational burden based on genomic regions unlikely to undergo loss
Findings from a phase II clinical study of combined PD1, BRAF and MEK inhibition
Evidence for efficacy is based on the results from the KEYNOTE-091 study
Findings from a large cohort of patients with advanced non-small cell lung cancer demonstrate substantially different gain in survival by age
New indication concerns the treatment of patients with metastatic hormone-sensitive prostate cancer in combination with docetaxel and androgen deprivation therapy